Brum, Wagner S.

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., Langhough, R. E., Cody, K., Wilson, R., Carlsson, C. M., et al. (2024) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 884

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

Ashton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 436

A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases

Brum, W. S., Cullen, N. C., Janelidze, S., Ashton, N. J., Zimmer, E. R., Therriault, J., Benedet, A. L., Rahmouni, N., Tissot, C., Stevenson, J., et al. (2023) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 248

Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays

Ashton, N. J., Puig‐Pijoan, A., Milà‐Alomà, M., Fernández‐Lebrero, A., García‐Escobar, G., González‐Ortiz, F., Kac, P. R., Brum, W. S., Benedet, A. L., Lantero‐Rodriguez, J., et al. (2023) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 230

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease

Ashton, N. J., Benedet, A. L., Pascoal, T. A., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Mathotaarachchi, S., Therriault, J., Savard, M., Chamoun, M., et al. (2022) · eBioMedicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 184

Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability

Therriault, J., Janelidze, S., Benedet, A. L., Ashton, N. J., Arranz Martínez, J., Gonzalez-Escalante, A., Bellaver, B., Alcolea, D., Vrillon, A., Karim, H., et al. (2024) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 131

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies.

Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., et al. (2023) · Nature Aging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 122

Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies

De Bastiani, M. A., Bellaver, B., Brum, W. S., Souza, D. G., Ferreira, P. C. L., Rocha, A. S., Povala, G., Ferrari-Souza, J. P., Benedet, A. L., Ashton, N. J., et al. (2023) · Brain, Behavior, and Immunity

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 57

Longitudinal plasma phosphorylated-tau217 and other related biomarkers in a non-demented Alzheimer’s risk- enhanced sample

Du, L., Langhough, R. E., Wilson, R. E., Reyes, R. E. R., Hermann, B. P., Jonaitis, E. M., Betthauser, T. J., Chin, N. A., Christian, B., Chaby, L., et al. (2024) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 46